High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
- 1 October 2005
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (10), 2211-2218
- https://doi.org/10.1111/j.1538-7836.2005.01484.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A new functional assay of thrombin activatable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2005
- Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma LevelsStroke, 2003
- Development of a Genotype 325–Specific proCPU/TAFI ELISAArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic StrokeStroke, 2003
- Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectorisThrombosis and Haemostasis, 2003
- Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidenceThrombosis and Haemostasis, 2003
- Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by AngiographyThrombosis and Haemostasis, 2002
- Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery DiseaseThrombosis and Haemostasis, 2000
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Classification and natural history of clinically identifiable subtypes of cerebral infarctionThe Lancet, 1991